428 related articles for article (PubMed ID: 29618348)
41. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.
Wu M; Dong B; Cao A; Li H; Liu J
Atherosclerosis; 2012 Oct; 224(2):401-10. PubMed ID: 22954675
[TBL] [Abstract][Full Text] [Related]
42. Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice CSK9PC57BL/6.
Mbikay M; Sirois F; Gyamera-Acheampong C; Wang GS; Rippstein P; Chen A; Mayne J; Scott FW; Chrétien M
J Diabetes; 2015 Jan; 7(1):74-84. PubMed ID: 24548670
[TBL] [Abstract][Full Text] [Related]
43. Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations.
Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
Atherosclerosis; 2016 May; 248():17-26. PubMed ID: 26978583
[TBL] [Abstract][Full Text] [Related]
44. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
Da Dalt L; Ruscica M; Bonacina F; Balzarotti G; Dhyani A; Di Cairano E; Baragetti A; Arnaboldi L; De Metrio S; Pellegatta F; Grigore L; Botta M; Macchi C; Uboldi P; Perego C; Catapano AL; Norata GD
Eur Heart J; 2019 Jan; 40(4):357-368. PubMed ID: 29982592
[TBL] [Abstract][Full Text] [Related]
45. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
[TBL] [Abstract][Full Text] [Related]
46. Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor.
Grin PM; Dwivedi DJ; Chathely KM; Trigatti BL; Prat A; Seidah NG; Liaw PC; Fox-Robichaud AE
Sci Rep; 2018 Jul; 8(1):10496. PubMed ID: 30002483
[TBL] [Abstract][Full Text] [Related]
47. Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells.
Gao WY; Chen PY; Chen SF; Wu MJ; Chang HY; Yen JH
J Agric Food Chem; 2018 Jun; 66(24):6083-6093. PubMed ID: 29862818
[TBL] [Abstract][Full Text] [Related]
48. Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor.
Topchiy E; Cirstea M; Kong HJ; Boyd JH; Wang Y; Russell JA; Walley KR
PLoS One; 2016; 11(5):e0155030. PubMed ID: 27171436
[TBL] [Abstract][Full Text] [Related]
49. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M
Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582
[TBL] [Abstract][Full Text] [Related]
50. Differential cholesterol uptake in liver cells: A role for PCSK9.
Luquero A; Vilahur G; Casani L; Badimon L; Borrell-Pages M
FASEB J; 2022 May; 36(5):e22291. PubMed ID: 35344222
[TBL] [Abstract][Full Text] [Related]
51. Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.
Kitamura K; Okada Y; Okada K; Kawaguchi Y; Nagaoka S
Mol Nutr Food Res; 2017 Aug; 61(8):. PubMed ID: 28181408
[TBL] [Abstract][Full Text] [Related]
52. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
[TBL] [Abstract][Full Text] [Related]
53. Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells.
Wu YR; Li L; Sun XC; Wang J; Ma CY; Zhang Y; Qu HL; Xu RX; Li JJ
Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):322-332. PubMed ID: 33500108
[TBL] [Abstract][Full Text] [Related]
54. Inflammation Induces Lipid Deposition in Kidneys by Downregulating Renal PCSK9 in Mice with Adriamycin-Induced Nephropathy.
Zhang G; Li Q
Med Sci Monit; 2019 Jul; 25():5327-5335. PubMed ID: 31317882
[TBL] [Abstract][Full Text] [Related]
55. Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells.
Chen HC; Chen PY; Wu MJ; Tai MH; Yen JH
PLoS One; 2016; 11(9):e0162414. PubMed ID: 27617748
[TBL] [Abstract][Full Text] [Related]
56. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
[TBL] [Abstract][Full Text] [Related]
57. Proprotein convertase subtilisin/kexin 9 inhibitor downregulates microRNA-130a-3p expression in hepatocytes to alleviates atherosclerosis progression.
Xu J; Zuo J; Han C; Li T; Jin D; Zhao F; Cong H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1727-1736. PubMed ID: 37721554
[TBL] [Abstract][Full Text] [Related]
58. Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity.
Du Y; Li S; Cui CJ; Zhang Y; Yang SH; Li JJ
J Transl Med; 2016 Sep; 14(1):276. PubMed ID: 27663646
[TBL] [Abstract][Full Text] [Related]
59. Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production.
Kamada Y; Yamamoto A; Fujiyoshi A; Koseki M; Morishita K; Asuka T; Takamatsu S; Sakata Y; Takehara T; Taniguchi N; Miyoshi E
Biochem Biophys Res Commun; 2020 Jun; 527(3):682-688. PubMed ID: 32423823
[TBL] [Abstract][Full Text] [Related]
60. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
